Apatinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Unresectable hepatocellular carcinoma, first line, in combination with camrelizumab (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the US

Also approved (3)
CN
  • Unresectable hepatocellular carcinoma, first line, in combination with camrelizumabbiospace.com
  • Advanced hepatocellular carcinoma (second line), approved late 2020pmc.ncbi.nlm.nih.gov
  • Advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior systemic chemotherapy regimensOutside this platform's coveragepmc.ncbi.nlm.nih.gov
Product first approved 2014

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (47)
Hepatocellular Carcinoma
NCT06172205 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2029-07-31 · BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
What this study did
NCT06485466 · Guohui Xu
2024-08-10 – 2028-06-30 · Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
What this study did
NCT04639180 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-01 – 2026-07-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05320692 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-09 – 2026-07-30 · Hepatocellular Carcinoma
What this study did
NCT05313282 · Sun Yat-sen University
2022-06-15 – 2025-06-01 · C-staged Hepatocellular Carcinoma in BCLC Classification
What this study did
NCT04985136 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-26 – 2021-12-29 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
Non-Small Cell Lung Cancer
NCT02824458 · Sun Yat-sen University
2016-06 – 2023-12 · EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
What this study did
NCT04203485 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-15 – 2022-05-31 · PD-L1 Positive Non-small Cell Lung Cancer
What this study did
NCT03428022 · Shenzhen People's Hospital
2017-12-01 – 2020-12-31 · NSCLC, Apatinib, EGFR-TKI
What this study did
Other / comorbidity
NCT07267806 · Linhui Peng
2025-10-31 – 2032-10 · Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
What this study did
NCT06255392 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-06-12 – 2031-03 · Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
What this study did
NCT07371910 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-06-12 – 2031-03 · Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
What this study did
NCT06925243 · Zuoyi Jiao
2025-04-15 – 2030-12-31 · Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR, ORR,OS,PFS
What this study did
NCT06889688 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-02-21 – 2029-06-01 · Breast Cancer Stage IV, Triple -Negative Breast Cancer
What this study did
NCT06438627 · XIANG YANQUN
2024-05-30 – 2029-05-30 · Nasopharyngeal Carcinoma
What this study did
NCT06447623 · Fudan University
2024-06-11 – 2029-02-01 · Advanced Breast Cancer, HR+/HER2- Breast Cancer
What this study did
NCT07314203 · Fujian Medical University
2026-12-25 – 2028-08-25 · Gastric Cancer, Surgery
What this study did
NCT05854849 · Sun Yat-sen University
2023-05-01 – 2027-12-01 · Nasopharyngeal Carcinoma
What this study did
NCT06913777 · Fudan University
2025-04-08 – 2027-04-15 · Neoadjuvant Therapy
What this study did
NCT05789043 · Peking University Cancer Hospital & Institute
2023-03-21 – 2027-02-15 · Acral Melanoma
What this study did
NCT06188455 · The First Affiliated Hospital of Xiamen University
2024-12-01 – 2026-12-01 · Ovarian Cancer
What this study did
NCT06539091 · Anhui Provincial Hospital
2024-10-01 – 2026-10-01 · Epithelial Ovarian Cancer, Efficacy, Safety, Bone Mineral Density, Tolerability
What this study did
NCT04342910 · Jiangsu HengRui Medicine Co., Ltd.
2020-09-21 – 2026-09-01 · Gastric Cancer
What this study did
NCT05889871 · Fudan University
2023-06-01 – 2026-06-01 · HR+/HER2-breast Cancer
What this study did
NCT03355612 · Tianjin Medical University Cancer Institute and Hospital
2017-12-20 – 2025-12-20 · Gastric Carcinoma
What this study did
NCT04296370 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-13 – 2025-06-30 · Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
What this study did
NCT04229615 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-02 – 2024-04-01 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT03889626 · Fudan University
2019-03-22 – 2024-03-22 · Stomach Neoplasms, Gastrointestinal Neoplasms, Stomach Diseases, Digestive System Neoplasms, Capecitabine, Apatinib, Neoplasms, Molecular Mechanisms of Pharmacological Action
What this study did
NCT03048877 · Peking Union Medical College Hospital
2016-12 – 2023-12-31 · Differentiated Thyroid Cancer
What this study did
NCT02875457 · Third Military Medical University
2016-09 – 2023-09 · Small Cell Lung Cancer
What this study did
NCT05049681 · Feng Wang
2021-12-05 – 2023-06-30 · Esophageal Cancer
What this study did
NCT03764293 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-10 – 2023-06-14 · Locally Advanced or Metastatic and Unresectable HCC
What this study did
NCT04335006 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-14 – 2023-04-14 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT03365765 · Huashan Hospital
2018-02-12 – 2022-12-31 · Apatinib
What this study did
NCT04000295 · Jiangsu HengRui Medicine Co., Ltd.
2019-08-16 – 2022-07 · Ovarian Cancer
What this study did
NCT04490421 · Fuzhou General Hospital
2020-08-01 – 2022-02-01 · Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors
What this study did
NCT03986385 · Hebei Medical University
2019-06-01 – 2021-01-31 · Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03598348 · Huazhong University of Science and Technology
2018-01-16 – 2020-10-16 · Gastric Cancer
What this study did
NCT03042611 · Elevar Therapeutics
2017-03-14 – 2020-09-23 · Gastric Cancer, Gastric Adenocarcinoma
What this study did
NCT03651219 · Beijing Chest Hospital
2018-09-08 – 2020-08-08 · Small Cell Lung Cancer
What this study did
NCT03100955 · Qingdao University
2017-03-01 – 2019-08-01 · Progression Free Survival
What this study did
NCT02537171 · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
2015-07 – 2016-10 · Gastric Cancer
What this study did
NCT01512745 · Jiangsu HengRui Medicine Co., Ltd.
2011-01 – 2013-05 · Advanced or Metastatic Gastric Cancer
What this study did
Phase 2/3 (19)
Hepatocellular Carcinoma
NCT06739317 · Sun Yat-sen University
2025-01-01 – 2031-06-30 · Unresectable Hepatocellular Carcinoma (HCC)
What this study did
NCT06796803 · Shanghai Zhongshan Hospital
2025-02-20 – 2030-02-28 · Potentially Resectable Hepatocellular Carcinoma
What this study did
NCT05062837 · Guangxi Medical University
2021-06-01 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT04521153 · Shanghai Zhongshan Hospital
2021-03-25 – 2026-03-01 · Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
What this study did
NCT02702323 · Zhejiang Cancer Hospital
2016-03 – 2019-03 · Hepatocellular Carcinoma, Pulmonary Metastasis
What this study did
Non-Small Cell Lung Cancer
NCT04968002 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-08-01 – 2022-10-01 · Non-small Cell Lung Cancer
What this study did
NCT02780778 · Tianjin Medical University Cancer Institute and Hospital
2016-05 – 2017-12 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04803539 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-01 – 2033-09-01 · Breast Cancer
What this study did
NCT07589244 · Guangzhou Virotech Pharmaceutical Co., Ltd.
2026-05-13 – 2029-06-30 · HCC
What this study did
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04208347 · Ruijin Hospital
2019-12-18 – 2027-12 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT03580395 · Hebei Medical University Fourth Hospital
2017-06-01 – 2022-12 · Breast Cancer
What this study did
NCT03285906 · Tianjin Medical University Cancer Institute and Hospital
2017-03-01 – 2019-12 · Esophagus Cancer, Stage III, Esophageal Gastric Cardia Type Metaplasia, Esophagus Cancer, Stage IV
What this study did
NCT02510469 · Hebei Medical University
2015-07 – 2018-07 · Gastric Cancer
What this study did
NCT02711007 · GUO WEI
2016-03 – 2018-01-08 · Osteosarcoma, Metastasis
What this study did
NCT02509806 · Hebei Medical University
2015-07 – 2017-12 · Gastric Cancer
What this study did
NCT02409199 · Shanghai Zhongshan Hospital
2015-06 – 2017-03 · Gastric Carcinoma
What this study did
NCT00970138 · Fudan University
2009-06 – 2010-12 · Gastric Carcinoma
What this study did
Phase 2 (369)
Hepatocellular Carcinoma
NCT07682272 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-07 – 2029-07 · Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
What this study did
NCT07324473 · First Affiliated Hospital of Chongqing Medical University
2026-01-01 – 2029-01-01 · Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
What this study did
NCT07314372 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-02-01 – 2028-12 · Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
What this study did
NCT07749859 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-08 – 2028-12 · Advanced Unresectable Hepatocellular Carcinoma
What this study did
NCT07154082 · Wei Zhang
2025-12-30 – 2028-07-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06360042 · Peking University Cancer Hospital & Institute
2024-01-01 – 2028-03-31 · Unresectable Hepatocellular Carcinoma
What this study did
NCT06607107 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-02-17 – 2028-01-11 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT06538935 · Fujian Cancer Hospital
2025-01 – 2027-12 · Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase Inhibitor
What this study did
NCT06454578 · Qilu Hospital of Shandong University
2024-07-24 – 2027-06 · Carcinoma, Hepatocellular
What this study did
NCT07192848 · Song Peng
2025-09 – 2027-06 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT06363825 · Fujian Medical University
2024-04-12 – 2027-05-11 · Advanced Hepatocellular Carcinoma
What this study did
NCT06546280 · Zhujiang Hospital
2024-08-26 – 2026-09-01 · Hepatocellular Carcinoma
What this study did
NCT05412589 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-06-10 – 2026-07-31 · Stage III Hepatocellular Cancer (CNLC Staging)
What this study did
NCT06349317 · Yongyi Zeng
2024-04-22 – 2026-06 · Hepatocellular Carcinoma
What this study did
NCT04930315 · Zhejiang University
2021-09-15 – 2026-04-30 · Hepatocellular Carcinoma
What this study did
NCT06482008 · Sun Yat-sen University
2024-06-19 – 2026-02-01 · Hepatocellular Carcinoma
What this study did
NCT04191889 · Sun Yat-sen University
2020-04-13 – 2025-12-31 · C-staged Hepatocellular Carcinoma in BCLC Classification
What this study did
NCT05839197 · Wan-Guang Zhang
2023-05-05 – 2025-04-15 · Macrotrabecular Massive Hepatocellular Carcinoma
What this study did
NCT04850040 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2021-05-06 – 2024-12-31 · Hepatocellular Carcinoma Resectable
What this study did
NCT05760430 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-12-14 – 2024-12 · Hepatocellular Carcinoma
What this study did
NCT05367687 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-01 – 2024-11-15 · Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
What this study did
NCT04701060 · Tianjin Medical University Cancer Institute and Hospital
2021-01-26 – 2024-10-04 · Resectable Hepatocellular Carcinoma
What this study did
NCT04724226 · Sun Yat-sen University
2021-09-01 – 2024-08-31 · Hepatocellular Carcinoma
What this study did
NCT05099848 · Shandong Cancer Hospital and Institute
2021-03-17 – 2024-05-31 · Hepatocellular Carcinoma
What this study did
NCT05550025 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-12-17 – 2024-02-11 · Hepatocellular Carcinoma
What this study did
NCT04479527 · Peking University Cancer Hospital & Institute
2021-04 – 2023-12-31 · Hepatocellular Carcinoma
What this study did
NCT05171309 · Nanfang Hospital, Southern Medical University
2021-01-01 – 2023-12-31 · Hepatocellular Carcinoma
What this study did
NCT04204577 · Chinese PLA General Hospital
2019-11-01 – 2023-11 · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
What this study did
NCT04826406 · Hunan Cancer Hospital
2021-02-03 – 2023-08-30 · Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
What this study did
NCT03839550 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2019-02-15 – 2023-02-28 · Hepatocellular Carcinoma
What this study did
NCT04523662 · Beijing Tsinghua Chang Gung Hospital
2020-08-30 – 2022-08-01 · Hepatocellular Carcinoma
What this study did
NCT04411706 · Xin-Hua Xu
2020-06-21 – 2022-06-01 · Hepatocellular Carcinoma
What this study did
NCT04297202 · The First Affiliated Hospital with Nanjing Medical University
2019-12-01 – 2021-12-01 · Hepatocellular Carcinoma
What this study did
NCT03463876 · Jiangsu HengRui Medicine Co., Ltd.
2018-03-08 – 2021-03-10 · Hepatocellular Carcinoma
What this study did
NCT03793725 · Yanqiao Zhang
2019-01-30 – 2021-01-30 · Hepatocellular Carcinoma
What this study did
NCT04014101 · Shanghai Zhongshan Hospital
2019-06-01 – 2020-10-01 · Hepatocellular Carcinoma
What this study did
NCT03261791 · Shanghai Zhongshan Hospital
2017-07-20 – 2020-04-20 · Carcinoma, Hepatocellular
What this study did
NCT03510416 · Shanghai Zhongshan Hospital
2018-05-01 – 2019-12-31 · Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
What this study did
NCT03511703 · Guangxi Medical University
2018-05-01 – 2019-06-30 · Hepatocellular Carcinoma
What this study did
NCT03046979 · Tianjin Medical University Cancer Institute and Hospital
2016-12 – 2018-12 · Hepatocellular Carcinoma
What this study did
NCT01192971 · Jiangsu HengRui Medicine Co., Ltd.
2010-06 – 2013-07 · Advanced Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT02493582 · The First People's Hospital of Changzhou
2015-07 – 2033-07 · Adenocarcinoma of Lung
What this study did
NCT03164694 · Sun Yat-sen University
2017-05-20 – 2027-05-20 · Lung Cancer
What this study did
NCT07031154 · The First Affiliated Hospital of Xiamen University
2025-06-30 – 2027-02-01 · Non-Small Cell Lung Cancer, Adebrelimab, Apatinib
What this study did
NCT06700421 · Wei Zhou
2024-08-13 – 2026-12-31 · Unresectable Locally Advanced Non-small Cell Lung Cancer
What this study did
NCT04379739 · Shanghai Pulmonary Hospital, Shanghai, China
2020-07-26 – 2026-12-30 · Non Small Cell Lung Cancer
What this study did
NCT04506242 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2020-09-15 – 2025-12-30 · NSCLC
What this study did
NCT05932264 · Sun Yat-sen University
2023-07 – 2025-12 · NSCLC, Non-small Cell Lung Cancer
What this study did
NCT04749394 · Chinese Academy of Medical Sciences
2021-03-17 – 2025-06 · Locally Advanced Non-Small Cell Lung Cancer
What this study did
NCT04425135 · The First Affiliated Hospital of Xiamen University
2020-07 – 2025-01 · Lung Neoplasms
What this study did
Phase 1/2 (32)
Hepatocellular Carcinoma
NCT05924997 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2026-06-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT04035876 · Zhejiang University
2019-07-16 – 2021-12-31 · Hepatocellular Carcinoma, Liver Transplant
What this study did
NCT02727309 · Peking University Cancer Hospital & Institute
2015-10 – 2019-03 · Hepatocellular Carcinoma
What this study did
NCT02942329 · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
2016-10 – 2018-10 · Gastric Cancer, Hepatocellular Carcinoma
What this study did
NCT02772029 · The First Affiliated Hospital of Zhengzhou University
2016-05 – 2017-09 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04133337 · Sichuan Cancer Hospital and Research Institute
2019-11-01 – 2021-06 · Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms, Non-small-cell Lung Cancer
What this study did
NCT03201146 · West China Hospital
2017-06-27 – 2020-08-01 · Lung Cancer, Non Small Cell Lung Cancer, Combination Chemotherapy, Apatinib
What this study did
Other / comorbidity
NCT07587034 · Shanghai Zhongshan Hospital
2026-06 – 2029-12 · Liver Cancer
What this study did
NCT07802184 · West China Hospital
2026-09-21 – 2029-05-01 · Metastatic Pancreatic Cancer
What this study did
NCT07479732 · Peking University People's Hospital
2026-03-05 – 2028-01-01 · Osteosarcoma, Osteosarcoma Metastatic
What this study did
NCT06607770 · Zhou Chengzhi
2024-09-01 – 2027-08 · Lung Cancer
What this study did
NCT06592287 · Xianglin Yuan
2024-09-30 – 2026-09-30 · Advanced Gastric Cancer
What this study did
NCT05742750 · Sun Yat-sen University
2023-04-27 – 2026-05-30 · Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
What this study did
NCT05027386 · Sun Yat-sen University
2021-08-26 – 2026-02-04 · Neuroblastoma
What this study did
NCT05559008 · Ruijin Hospital
2022-09-30 – 2026-01-26 · Peripheral T Cell Lymphoma
What this study did
NCT05019690 · Fujian Cancer Hospital
2021-10-01 – 2025-06-01 · Advanced Triple Negative Breast Cancer
What this study did
NCT03599778 · Anhui Provincial Hospital
2018-09-01 – 2025-01-30 · Gastric Carcinoma
What this study did
NCT04476459 · Huiqiang Huang
2020-07-23 – 2023-08-01 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
What this study did
NCT04659785 · Tianjin Medical University Second Hospital
2020-07-01 – 2022-12-31 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT04201990 · ShiYue Li
2019-12 – 2022-12 · Lung Cancer
What this study did
NCT04446091 · Zhejiang Cancer Hospital
2020-07-01 – 2022-07-01 · Colorectal Cancer
What this study did
NCT04572542 · The First Affiliated Hospital of Xiamen University
2020-01-01 – 2022-06-01 · Locally Advanced or Metastatic Gastric Adenocarcinoma
What this study did
NCT04182724 · Chinese PLA General Hospital
2019-11-12 – 2022-05-12 · Advanced Gastric Cancer
What this study did
NCT04202978 · Zhongshan Hospital Xiamen University
2020-03-01 – 2021-11-01 · Hepatic Metastasis of Colorectal Cancer
What this study did
NCT04067986 · Zhongshan Hospital Xiamen University
2019-08-20 – 2021-10-31 · Colorectal Cancer Recurrent
What this study did
NCT03654612 · China International Medical Foundation
2018-10-16 – 2021-09-01 · Head and Neck Cancer
What this study did
NCT03707028 · Elevar Therapeutics
2018-10-01 – 2021-08-24 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04286711 · China Medical University, China
2020-03 – 2021-06 · Advanced Gastric Cancer
What this study did
NCT03868852 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2019-01-01 – 2020-04-01 · Childhood Rhabdomyosarcoma
What this study did
NCT02844881 · The First People's Hospital of Lianyungang
2016-07 – 2018-07 · Advanced Solid Tumors, Excluding T Cell Lymphoma
What this study did
NCT02848794 · The First People's Hospital of Lianyungang
2016-07 – 2018-07 · High-grade Glioma
What this study did
NCT01497704 · Elevar Therapeutics
2012-04 – 2015-05 · Cancer Patients With Solid Tumors
What this study did
Phase 1 (33)
Hepatocellular Carcinoma
NCT04665362 · Liang Peng
2021-01-25 – 2022-10-30 · Advanced/Metastatic Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04390984 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-26 – 2021-03 · NSCLC
What this study did
NCT03050411 · Peking University Third Hospital
2016-05 – 2019-10 · Nonsmall Cell Lung Cancer
What this study did
NCT02691871 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2016-02 – 2016-12 · Lung Adenocarcinoma
What this study did
Other / comorbidity
NCT06181032 · First Affiliated Hospital of Fujian Medical University
2023-12-23 – 2029-02-23 · Biliary Tract Malignancies
What this study did
NCT06769425 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-07 – 2026-08-31 · Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC, Advanced Prostate Cancer, Advanced Gastric Cancer
What this study did
NCT04074564 · HRYZ Biotech Co.
2019-11-22 – 2024-12-05 · Sarcoma
What this study did
NCT05001412 · Zhou Chengzhi
2021-01-27 – 2024-01-25 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT04393506 · Shanghai Jiao Tong University School of Medicine
2020-04-23 – 2023-11-10 · Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy
What this study did
NCT03491631 · Jiangsu HengRui Medicine Co., Ltd.
2018-11-20 – 2023-09 · Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
What this study did
NCT04073615 · Elevar Therapeutics
2019-11-18 – 2023-05-31 · Metastatic Colorectal Cancer
What this study did
NCT05287360 · Elevar Therapeutics
2021-12-30 – 2022-03-24 · Healthy
What this study did
NCT03396211 · Elevar Therapeutics
2017-12-22 – 2022-03-16 · Cancer
What this study did
NCT03075462 · Jiangsu HengRui Medicine Co., Ltd.
2017-03-09 – 2021-12-13 · Ovarian Cancer, Triple Negative Breast Cancer
What this study did
NCT04428086 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-27 – 2021-08-22 · Solid Tumor, Adult
What this study did
NCT04457180 · Jiangsu HengRui Medicine Co., Ltd.
2020-11-16 – 2021-06-19 · Advanced Solid Tumor
What this study did
NCT04322552 · Jiangsu HengRui Medicine Co., Ltd.
2020-03-12 – 2021-05-03 · Advanced Solid Tumor
What this study did
NCT04414852 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-05 – 2021-04-30 · Subjects With Impaired Renal Function and Healthy Subjects
What this study did
NCT03945604 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-04 – 2021-02-09 · Triple Negative Breast Cancer
What this study did
NCT04341090 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-13 – 2020-07-06 · Healthy Subjects
What this study did
NCT03407976 · University of Utah
2018-06-19 – 2020-07-02 · Advanced Malignancies, Urothelial Carcinoma, MSI-H or dMMR Solid Tumors, Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT03645200 · Tianjin Medical University Second Hospital
2019-07-01 – 2020-06-01 · Advanced Cancer
What this study did
NCT03243643 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2017-08-08 – 2019-12 · Advanced Cancer
What this study did
NCT03244774 · Fujian Cancer Hospital
2018-01-01 – 2019-06-30 · Gastric Adenocarcinoma
What this study did
NCT02711969 · Bukwang Pharmaceutical
2016-03 – 2019-03 · Gastric Cancer
What this study did
NCT02645864 · Peking University
2016-01 – 2018-12 · Esophageal Squamous Cell Carcinoma
What this study did
NCT03245307 · Jiangsu HengRui Medicine Co., Ltd.
2017-08-22 – 2018-09-30 · Cytochrome P450 Interaction
What this study did
NCT03071042 · Sir Run Run Shaw Hospital
2015-10 – 2018-06 · Metastatic Gastric Adenocarcinoma
What this study did
NCT03026881 · Jiangsu HengRui Medicine Co., Ltd.
2017-01 – 2018-06 · Recurrent and Metastatic Gastric Cancer
What this study did
NCT03276156 · Zhejiang Cancer Hospital
2016-02-23 – 2018-02-22 · Gastric Cancer
What this study did
NCT02836171 · Jiangsu HengRui Medicine Co., Ltd.
2016-07 – 2017-02 · Neoplasms
What this study did
NCT02836821 · Jiangsu HengRui Medicine Co., Ltd.
2016-05 – 2017-02 · Neoplasms
What this study did
NCT00633490 · Fudan University
2007-07 – 2008-06 · Tumor
What this study did
Phase 4 (10)
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
NCT03384511 · Shandong Cancer Hospital and Institute
2016-09-30 – 2018-01-28 · Malignancies, Stomach Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer, Ovary Cancer, Cervical Cancer
What this study did
Other / comorbidity
NCT05029453 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-08-26 – 2023-03-03 · Gastric Cancer, Randomized Controlled Study
What this study did
NCT03475589 · Sun Yat-sen University
2018-02-26 – 2021-12 · Stage IV Cancer
What this study did
NCT02426034 · Jiangsu HengRui Medicine Co., Ltd.
2015-05-15 – 2020-09-03 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03631862 · Zhengzhou University
2018-09-01 – 2019-12-31 · Newly Diagnosed Peripheral T-cell Lymphoma
What this study did
NCT03725423 · Xuzhou Central Hospital
2018-10 – 2019-06 · Lung Squamous Cell Carcinoma
What this study did
NCT03376958 · Zhengzhou University
2017-01-01 – 2019-04-30 · Relapsed and Refractory, Diffuse Large B Cell Lymphoma
What this study did
NCT02776527 · Tianjin Medical University Cancer Institute and Hospital
2016-04 – 2017-04 · Gastric Cancer
What this study did
Early phase / not applicable (29)
Hepatocellular Carcinoma
NCT06893887 · Nanjing Tianyinshan Hospital
2025-05-22 – 2028-12-15 · Hepatocellular Carcinoma(HCC)
What this study did
NCT04559607 · Zhongda Hospital
2020-09-11 – 2026-01-31 · Hepatocellular Carcinoma
What this study did
NCT03722875 · Shanghai Zhongshan Hospital
2018-12-01 – 2020-03-01 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04950400 · Beijing Chest Hospital
2021-07-07 – 2024-04-04 · Non-small Cell Lung Cancer
What this study did
NCT03634059 · Hebei Medical University Fourth Hospital
2018-08-15 – 2020-08-15 · NSCLC
What this study did
NCT03594682 · Beijing Chest Hospital
2018-08 – 2020-07 · NSCLC Stage IV, NSCLC Stage IIIB
What this study did
Other / comorbidity
NCT07371871 · Anhui Provincial Cancer Hospital
2026-01-08 – 2028-12-31 · Advanced Gastric Cancer
What this study did
NCT05751733 · Xiangya Hospital of Central South University
2023-02-01 – 2027-01-01 · Gastrointestinal Stromal Tumors
What this study did
NCT03743428 · Shenzhen People's Hospital
2020-10-22 – 2026-12-31 · Colorectal Neoplasms
What this study did
NCT06102707 · Qilu Hospital of Shandong University
2023-11-01 – 2026-11-01 · Ovarian Cancer Recurrent
What this study did
NCT06480864 · Yunpeng Liu
2024-08-09 – 2026-08 · Small Cell Lung Cancer
What this study did
NCT05653817 · First Affiliated Hospital Xi'an Jiaotong University
2023-01-31 – 2026-01-31 · Cholangiocarcinoma
What this study did
NCT04501705 · Beijing Sanbo Brain Hospital
2020-08-18 – 2025-08-31 · Recurrent Atypical/malignant Meningioma
What this study did
NCT05380986 · Henan Cancer Hospital
2022-05-20 – 2025-05-01 · Solid Tumor
What this study did
NCT04366128 · Rong Tao
2020-04-25 – 2024-12-30 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT03228043 · Nanchong Central Hospital
2020-03-01 – 2023-03-01 · Apatinib, Outcome, Fatal, Colorectal Cancer, Surgery, Adjuvant Chemotherapy
What this study did
NCT04507750 · Qianfoshan Hospital
2020-08-10 – 2022-08-30 · Immune Checkpoint Inhibition
What this study did
NCT03671265 · Tianjin Medical University Cancer Institute and Hospital
2018-09-17 – 2021-09-01 · Esophageal Cancer
What this study did
NCT04690231 · Peking University People's Hospital
2020-12-01 – 2021-06-01 · Effect of Drug, Toxicity, Drug, Secondary Resistance
What this study did
NCT04174339 · Fujian Cancer Hospital
2019-12-10 – 2021-05-02 · Advanced Gastric Adenocarcinoma
What this study did
NCT03029013 · Third Military Medical University
2017-01 – 2020-12 · Cervical Cancer
What this study did
NCT04260113 · Peking University People's Hospital
2019-10-01 – 2020-04-01 · Efficacy, Toxicity, Drug
What this study did
NCT03349827 · Wuhan University
2018-01-05 – 2020-03-20 · Peritoneal Metastases From Gastric Cancer
What this study did
NCT02764268 · Jiangsu HengRui Medicine Co., Ltd.
2016-11-02 – 2019-04-15 · Gastric Cancer
What this study did
NCT03255811 · DongMa
2017-03-25 – 2019-03-25 · Advanced Gastric Cancer
What this study did
NCT02998242 · Sichuan Provincial People's Hospital
2016-05-10 – 2017-12-10 · Quality of Life
What this study did
NCT03491371 · Peking University People's Hospital
2015-06-01 – 2017-02-01 · Efficacy, Toxicity
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Other / comorbidity
NCT06351020 · LaNova Medicines Zhejiang Co., Ltd.
2024-06-24 – 2026-12-15 · Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
What this study did
NCT06346392 · AstraZeneca
2024-03-04 – 2026-10-14 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04714190 · RemeGen Co., Ltd.
2021-03-24 – 2025-06-30 · Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
What this study did
Phase 2/3 (1)
Hepatocellular Carcinoma
NCT07309419 · Shanghai Zhongshan Hospital
2025-12-22 – 2030-06-30 · Hepatocellular Carcinoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04581473 · CARsgen Therapeutics Co., Ltd.
2020-10-23 – 2038-06-30 · Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
Early phase / not applicable (1)
Hepatocellular Carcinoma
NCT03066557 · Jiangsu Cancer Institute & Hospital
2017-03-15 – 2018-12-31 · Hepatocellular Carcinoma
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Hepatocellular Carcinoma
NCT05613478 · The First Affiliated Hospital with Nanjing Medical University
2023-01-31 – 2027-11-01 · Hepatocellular Carcinoma, Immunotherapy, Preoperative
What this study did
NCT05198609 · Sun Yat-sen University
2022-01-17 – 2026-07-01 · Hepatocellular Carcinoma
What this study did
Phase 2 (5)
Hepatocellular Carcinoma
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT03520257 · Guangxi Medical University
2018-05-01 – 2019-06-30 · Hepatocellular Carcinoma
What this study did
NCT03114085 · First Affiliated Hospital of Guangxi Medical University
2017-05-20 – 2019-05-20 · Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT05342389 · Sixth Affiliated Hospital, Sun Yat-sen University
2022-05-01 – 2023-11-01 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05095636 · Fudan University
2021-03-17 – 2023-09 · Gastric Cancer, Metastasis
What this study did
Early phase / not applicable (1)
Hepatocellular Carcinoma
NCT03398122 · Tianjin Medical University Cancer Institute and Hospital
2017-11-14 – 2019-04-01 · Hepatocellular Carcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Apatinib: this drugPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 71 furthest-along competitors are listed; 539 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(84 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Apatinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (11)
November 2026 (1)
Phase 2GC/GEJCRecruiting
Est. primary completion 2026-11-30 · NCT07770113 · CT.gov ↗
What to watch
December 2026 (10)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06454578 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2026-12 · NCT06538935 · CT.gov ↗
What to watch
Phase 2Unresectable Biliary Tract CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06749730 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TreatmentRecruiting
Est. primary completion 2026-12 · NCT06576973 · CT.gov ↗
What to watch
Phase 2/3Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04208347 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Limited StageRecruiting
Est. primary completion 2026-12-01 · NCT06483282 · CT.gov ↗
What to watch
Phase 2Gestational Trophoblastic NeoplasiaRecruiting
Est. primary completion 2026-12-01 · NCT05139095 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT05062837 · CT.gov ↗
What to watch
Phase 2Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06831175 · CT.gov ↗
What to watch
Phase 2Digestive System CancersActive not recruiting
Est. primary completion 2026-12-31 · NCT06099821 · CT.gov ↗
What to watch
2027 (37)
January 2027 (1)
Phase 2Metastatic Pancreatic CarcinomaNot yet recruiting
Est. primary completion 2027-01-15 · NCT06759090 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Advanced Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-02-01 · NCT06745193 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-01 · NCT07031154 · CT.gov ↗
What to watch
Phase 3Advanced Breast Cancer, HR+/HER2- Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT06447623 · CT.gov ↗
What to watch
March 2027 (5)
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-03-01 · NCT06296563 · CT.gov ↗
What to watch
Phase 1/2Osteosarcoma, Osteosarcoma MetastaticRecruiting
Est. primary completion 2027-03-05 · NCT07479732 · CT.gov ↗
What to watch
Phase 2Resectable Intrahepatic Cholangiocarcinoma With High Risk of RecurrenceRecruiting
Est. primary completion 2027-03-31 · NCT06280508 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-03-31 · NCT07618546 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Solid TumorNot yet recruiting
Est. primary completion 2027-04-01 · NCT06537505 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06385873 · CT.gov ↗
What to watch
Phase 2AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06973330 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-06 · NCT07192848 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Recruiting
Est. primary completion 2027-06-01 · NCT06925516 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-06-20 · NCT07033819 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Biliary Tract Cancer (CCA)Recruiting
Est. primary completion 2027-06-30 · NCT07135544 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch
Phase 2Advanced Gastric Cancer, SHR1701Recruiting
Est. primary completion 2027-07-15 · NCT07294664 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Extensive StageNot yet recruiting
Est. primary completion 2027-07-25 · NCT06786312 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Gastric Cancer, Apatinib, BiomarkerRecruiting
Est. primary completion 2027-08 · NCT03219593 · CT.gov ↗
What to watch
Phase 2Mixed Hepatocellular-cholangiocarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07105748 · CT.gov ↗
What to watch
Phase 3Gastric Cancer, SurgeryNot yet recruiting
Est. primary completion 2027-08-25 · NCT07314203 · CT.gov ↗
What to watch
Phase 2Gastrointestinal Stromal TumorsRecruiting
Est. primary completion 2027-08-31 · NCT05905887 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Malignant Ascites, ApatinibRecruiting
Est. primary completion 2027-09 · NCT03020979 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-09-10 · NCT05192798 · CT.gov ↗
What to watch
December 2027 (12)
Phase 2Small Cell Lung Cancer Extensive StageRecruiting
Est. primary completion 2027-12 · NCT06749691 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-15 · NCT06893887 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2027-12-30 · NCT07334483 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07773363 · CT.gov ↗
What to watch
Phase 2Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2027-12-31 · NCT06764368 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07154082 · CT.gov ↗
What to watch
Phase 2Mucosal MelanomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07236528 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07314372 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
Phase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR …Recruiting
Est. primary completion 2027-12-31 · NCT06925243 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Gastric CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07371871 · CT.gov ↗
What to watch
2028 (19)
January 2028 (2)
Phase 2Gastric Cancer (GC), Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-01-01 · NCT07311408 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT07324473 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of StomachRecruiting
Est. primary completion 2028-02-01 · NCT07353684 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-02-20 · NCT06796803 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-03-01 · NCT06339619 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Rectal Cancer PatientsActive not recruiting
Est. primary completion 2028-05-29 · NCT07687433 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT07464756 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-07 · NCT07749859 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-07-31 · NCT06172205 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Limited-stage Small Cell Lung Cancer (LS-SCLC)Enrolling by invitation
Est. primary completion 2028-08-01 · NCT06773156 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT04803539 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CarcinomaNot yet recruiting
Est. primary completion 2028-09-26 · NCT07357532 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07874425 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-12-30 · NCT07569679 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07610629 · CT.gov ↗
What to watch
Phase 2/3HCCRecruiting
Est. primary completion 2028-12-31 · NCT07589244 · CT.gov ↗
What to watch
Phase 3Breast Cancer Stage IV, Triple -Negative Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07790419 · CT.gov ↗
What to watch
2029 (9)
January 2029 (1)
Phase 1/2Metastatic Pancreatic CancerRecruiting
Est. primary completion 2029-01-01 · NCT07802184 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1Biliary Tract MalignanciesRecruiting
Est. primary completion 2029-02-23 · NCT06181032 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Recurrent/Metastatic Endometrial CancerNot yet recruiting
Est. primary completion 2029-04-01 · NCT06771154 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 PositiveNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Hepato Cellular Carcinoma (HCC), Chemotherapy EffectRecruiting
Est. primary completion 2029-10 · NCT07267806 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1/2Liver CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07587034 · CT.gov ↗
What to watch
Phase 2Breast Neoplasms, Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-low Breast CancerNot yet recruiting
Est. primary completion 2029-12-30 · NCT07907354 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (Diagnosis)Not yet recruiting
Est. primary completion 2029-12-31 · NCT07904442 · CT.gov ↗
What to watch
Phase 2Melanoma, Immune Checkpoint InhibitorRecruiting
Est. primary completion 2029-12-31 · NCT07934927 · CT.gov ↗
What to watch
2030 (4)
June 2030 (1)
Phase 2Stomach NeoplasmsActive not recruiting
Est. primary completion 2030-06 · NCT02485015 · CT.gov ↗
What to watch
July 2030 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-07 · NCT02493582 · CT.gov ↗
What to watch
Phase 2Liver Cancer (Primary and Metastatic)Not yet recruiting
Est. primary completion 2030-07-01 · NCT07684040 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT06739317 · CT.gov ↗
What to watch
2031 (4)
March 2031 (2)
Phase 3Fludzoparib&#34; and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast CancerRecruiting
Est. primary completion 2031-03 · NCT06255392 · CT.gov ↗
What to watch
Phase 3Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast CancerActive not recruiting
Est. primary completion 2031-03 · NCT07371910 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-04-10 · NCT06992336 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Malignant Neoplasms of Digestive OrgansRecruiting
Est. primary completion 2031-08-06 · NCT05934331 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026Filing submittedRivoceranib NDA resubmitted to the FDA after July 2026 CRL
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterFDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗